natgillin/translations-raw huggingface dataset:
BAC (benzalkonium chloride) as an anti-microbial preservative, the concentration of BAC in the composition being greater than 0.0007 w/v% but less than 0.0035 w/v%; and water. A composition as in claim 1 wherein the composition satisfies Ph. 
BAC kao antimikrobni konzervans, te je koncentracija BAC u pripravku veća od 0,00001 m/v% ali manja od 0,0035 m/v%; i vodu, pri čemu je terapeutsko sredstvo suspendirano u otopini, i pri čemu se osmolalnost suspenzije nalazi u rasponu od 240 do 360 mOsm.
A compound of general formula (I) wherein 
Spoj s općom formulom (I) [image] naznačen time da
The invention further relates to the following aspects: A fusion protein comprising (i) an immunoglobulin molecule and (ii) two mutant interleukin-2 (IL-2) molecules comprising an amino acid mutation that reduces affinity of the mutant IL-2 molecule to the intermediate affinity IL-2 receptor, as compared to a wild-type IL-2 molecule. 
Fuzijski protein, naznačen time, da obuhvaća(i) molekulu imunoglobulina koja nije sposobna za specifično vezanje na antigen i (fi) dvije molekule mutantskog interleukina-2 (IL-2) koje obuhvaćaju mutaciju aminokiseline koja smanjuje afinitet mutantske IIL-2 molekule na srednji afinitet IL-2 receptora, u usporedbi s divljim tipom IL-2 molekule, pri čemu spomenute mutantske molekule IL-2 obuhvaćaju slijed SEQ ID NO; 58.
is a bond or substituted or unsubstituted alkylene, provided that if L2 is a bond, R5 is hydrogen; 
je veza, supstituirani ili nesupstituirani alkilen, supstituirani ili nesupstituirani heteroalkilen, -S-, -SO-, -SO2-, -O-, -NHSO2- ili -NR7-;
A compound of Formula I: or a pharmaceutically acceptable salt, ester or prodrug thereof, for use in a method of treating acute opioid toxicity or overdose for a period of over one hour comprising a single administration of the compound to a subject in need thereof, wherein; 
Spoj od formule: za uporabu u postupku liječenja akutne opioidne toksičnosti ili predoziranja tijemom razdoblja od preko jednog sata sadrži jednokratnu primjenu navedenog spoja subjektu kojem je nužno.
The ink cartridge of claim 1, wherein the at least one precursor pulse is sent to the at least one nozzle (103, 560) via precursor pulse wiring and the at least one firing pulse is sent to the at least one nozzle (103, 560) via firing pulse wiring separate and different from the precursor pulse wiring. 
Tintni uložak u skladu s patentnim zahtjevom 1, naznačen time što se najmanje jedan okidni predimpuls šalje u okidni otpornik (408) putem žica za predimpuls, a najmanje jedan okidni impuls se šalje u okidni otpornik (408) putem žica za okidni impuls, odvojenih i različitih od žica za predimpuls.
NB 11,000 A method of treating atopic dermatitis, said method comprising administering to a patient in need thereof an antibody or antigen-binding fragment thereof which specifically binds to a human interleukin-4 receptor, wherein the antibody or antigen-binding fragment comprises a heavy chain variable region (HCVR) comprising the three heavy chain CDRs (HCDR1, HCDR2 and HCDR3) from SEQ ID NO:162, and a light chain variable region (LCVR) comprising the three light chain CDRs (LCDR1, LCDR2 and LCDR3) from SEQ ID NO:164. 
Antitijelo ili njegov fragment koji se vezuje za antigen koji se specifično vezuje za humani interleukin-4 receptor (hIL-4R) (SEQ ID NO:274) za primjenu u metodi liječenja oboljenja ili poremećaja, naznačena time, što je oboljenje 1li poremećaj odabran iz skupine koja se sastoji od oboljenja pluća, upalnih poremećaja 1 alergijskih reakcija, pri čemu antitijelo ili njegov fragment sadrži varijabilnu regiju teškog lanca (HCVR) koja sadrži aminokiselinsku sekvencu prikazanu u SEQ ID NOQO:162 i varijabilnu regiju lakog lanca (LCVR) koja sadrži aminokiselinsku sekvencu prikazanu u SEQ ID NO:164.
The pharmaceutical composition for use according to claim 21, wherein the myeloproliferative disorder is myeloid metaplasia with myelofibrosis (MMM). 
Spoj ili sol za upotrebu prema patentnom zahtjevu 16, naznačen time da je navedeni mijeloproliferativni poremećaj mijeloidna metaplazija sa mijelofibrozom (MMM).
The process according to claim 1, wherein the filler of step b) and/or the at least one further filler of step e) is associated with a dispersing agent selected from the group consisting of homopolymers or copolymers of polycarboxylic acids and/or their salts or derivatives or esters thereof; esters based on acrylic acid, methacrylic acid, maleic acid, fumaric acid, itaconic acid; acryl amide or acrylic esters, methylmethacrylate, or any mixture thereof; and alkali polyphosphates, phosphonic-, citric- and tartaric acids and the salts or esters thereof; or any mixture thereof. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time da je punilo i/ili pigment iz koraka b) i/ili barem jedno dodatno punilo ili pigment is povezano s disperzijskim sredstvima odabranim iz skupine koja sadrži homopolimere ili kopolimere polikarboksilnih kiselina i/ili njihove soli ili derivate kao što su esteri bazirani na, npr., akrilnoj kiselini, metakrilnoj kiselini, maleinskoj kiselini, fumarnoj kiselini, itakonskoj kiselini; npr. akril amid ili akrilni esteri kao što su metilmetakrilat, ili njihove mješavine; alkalni polifosfati, fosfonska-, limunska- i vinska kiselina i njihove soli ili esteri; ili njihove mješavine.
The amount of DA1, DA2 and/or EOD1 polypeptide may be determined in one or more cells of the plant, preferably cells from an above-ground portion or tissue of the plant, such as the vasculature and primary and secondary meristems in the shoot. 
(a) uvođenje mutacije u nukleotidnu sekvencu biljne stanice, koja kodira polipeptid DA1 i/ili polipeptid EOD, ili koja regulira njegovu ekspresiju, te regeneriranje biljke iz mutirane stanice;
and R8 independently represent hydrogen; alkyl; cyano-alkyl; alkenyl; phenyl optionally mono-substituted by halogen, alkyl, alkoxy, —CF3, —OCF3, phenyl-alkyl or phenyl-carbonyl; phenyl, di-substituted with halogen, alkoxy and phenyl; phenyl-alkyl optionally substituted in the alkyl chain by phenyl or optionally substituted in the phenyl ring by methylendioxy; phenyl-alkyl which is di-substituted by halogen or mono-substituted by halogen, —CF3, —OCHF2, alkyl or alkylsulfanyl; naphthyl; naphthyl-alkyl; cycloalkyl, wherein cycloalkyl refers to a cyclopentyl or cyclohexyl group, wherein said groups are optionally substituted with an annulated benzene ring; pyridyl-alkyl; or thienyl-alkyl; or 
Ri R* neovisno predstavljaju vodik; alkil; cijano-alkil; alkenil; fenil opcijski mono-supstituiran sljedećima halogen, alkil, alkoksi, -CF:s, -OCF:, fenil-alkil ili fenil-karbonil; fenil di-supstituiran supstituentima neovisno odabranima od halogen, alkoksi 1 fenil; fenil-alkil opcijski supstituiran u alkilnoj polovici fenilom ili opcijski supstituiran u fenilnom prstenu s metilendioksi; fenil-alkil koji je di-supstituiran halogenom ili mono-supstituiran halogenom, -CF:3, -OCHF>, alkil ili alkilsulfanil; naftil; naftil-alkil; cikloalkil koji je opcijski supstituiran s aneliranim benzenovim prstenom; piridil-alkil; ili tienil-alkil; ili
A typical injectable preparation may be produced by aseptically placing 250 mg of compound of formula I into a vial, aseptically freeze-drying and sealing. 
Tipičan injektabilni preparat se može proizvesti aseptičkim postavljanjem 250 mg spoja formule I u epruvetu, aseptičkim sušenjem zamrzavanjem i zatvaranjem.
The energy savings system of claim 1 wherein the energy savings device is configured to be used for controllers for refrigerators; freezers; air conditioners; AC electric motors and AC voltage; single, bi- or poly-phase whole house energy savings devices; commercial and industrial energy savings devices; or AC voltage regulators. 
Sustav za uštedu energije iz zahtjeva 1, gdje je uređaj za uštedu energije izveden tako da se koristi za regulatore hladnjaka; zamrzivača; klima uređaja; AC električne motore i AC napon; jedno, bi -ili poli fazne uređaje za uštedu energije cijele kuće; uređaje za uštedu komercijalne te industrijske energije; ili regulatore AC napona.
re-suspending the third precipitate to form a suspension; and 
re-suspendiranje drugog taloga stvorenog u koraku (e), za tvorbu suspenzije,
The method according to claim 1, wherein the disease or disorder is colon cancer. 
Spoj ili farmaceutski sastav za uporabu prema zahtjevu 3, naznačen time, da bolest ili poremećaj je rak mozga.
This patent emphasizes the need of micronization and further wetting as the oral administration of nebivolol hydrochloride is impeded by the poor dissolution when in a normal crystalline form. In order to achieve a good dissolution the active ingredient has to be sufficiently wetted. 
Ovaj patent naglašava potrebu za mikronizacijom 1 daljnjim vlaženjem budući je oralna primjena nebivolol hidroklorida ometana slabim otapanjem kada je u normalnom kristalnom obliku da bi se postiglo dobro otapanje aktivna tvar se mora dovoljno vlažiti.
hyicus, Staphylococcus haemolyticus, Staphylococcus hominis, and Staphylococcus saccharolyticus, or from the group consisting of Clostridium difficile, Clostridium perfringens, Clostridium tetini, and Clostridium botulinum, or from the group consisting of Mycobacterium tuberculosis, Mycobacterium avium, Mycobacterium intracellulare, and Mycobacterium leprae, or from the group consisting of Chlamydia pneumoniae and Mycoplasma pneumoniae. 
hyicus, Staphylococcus haemolyticus, Staphylococcus hominis, i Staphylococcus saccharolyticus, ili iz grupe koja se sastoji od Clostridium difficile, Clostridium perfringens, Clostridium tetini, i Clostridium botulinum, ili iz grupe koja se sastoji od Mycobacterium tuberculosis, Mycobacterium avium, Mycobacterium intracellulare, i Mycobacterium leprae, ili iz grupe koja se sastoji od Chlamydia pneumoniae i Mycoplasma pneumoniae.
Typically, the casing may include around 5 - 25 wt% Plasticiser and up to around 50 wt.% of anti tack agent, preferably 1-10 wt.% of anti-tack agent. 
Tipično, kućište može uključivati oko 5 - 25 mas. % plasticizatora i do oko 50 mas. % sredstva protiv lijepljenja, poželjno 1 - 10 mas. % sredstva protiv lijepljenja.
Pharmaceutical according to claim 5, characterized in that it is an inhalable dry powder, an inhalable aerosol with or without propellant, or an inhalable suspension or solution. 
Farmaceutski proizvod sukladno patentnom zahtjevu 5, naznačen time, da je taj proizvod suhi prašak za inhaliranje, aerosol za inhaliranje sa ili bez potisnog plina ili inhalacijska suspenzija ili otopina.
The combinations of the invention can optionally comprise one or more additional active substances which are known to be useful in the treatment of respiratory disorders, such as B2-agonists, corticosteroids or glucocorticoids, leukotriene D4 inhibitors, inhibitors of egfr-kinase, p38 kinase inhibitors and/or NK1-receptor antagonists. 
Kombinacije sukladno predmetnom izumu po izboru mogu sadržavati jednu ili više dodatnih djelatnih tvari koje su poznate kao korisne u liječenju respiratornih poremećaja, poput inhibitora PDE4, B2 agonista ili glukokortikoida, inhibitora leukotnena D4, inhibitora egfr-kinaze, inhibitora p38 kinaze i/ili antagonista NK1-receptora.
The process of claim 1, wherein the residuum hydrocarbon comprises at least one of petroleum atmospheric or vacuum residua, deasphalted oils, deasphalter pitch, hydrocracked atmospheric tower or vacuum tower bottom, straight run vacuum gas oil, hydrocracked vacuum gas oil, fluid catalytically cracked (FCC) slurry oils, vacuum gas oil from an ebullated bed process, shale-derived oils, coal-derived oils, bioderived crude oils, tar sands bitumen, tall oils, black oils. The process of claim 1, wherein the coker is a delayed coker. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da ugljikovodični ostatak (10) sadržava barem jedan od ostaka atmosferske ili vakuumske destilacije nafte, deasfaltiranih ulja, smole za deasfaltiranje, hidrokrekiranog dna iz atmosferskog kolone ili vakuumske kolone, plinsko ulje dobiveno izravno iz vakuumske kolone, hidrokrekirano vakuumsko plinsko ulje, muljevita ulja iz fluid katalitičkog krekinga (FCC), plinsko ulje iz vakuumskog procesa s ebuliranim slojem, ulja dobivena iz škriljaca, ulja dobivena iz ugljena, biološka sirova ulja, bitumen katranskih pijesaka, visoka ulja, crna ulja.
In some embodiments, at least one emollient is selected from the groups consisting of diisopropyl adipate, isopropyl myristate, isopropyl palmitate, cetearyl octonoate, isopropyl isostearate, myristyl lactate, octyldodecanol, oleyl alcohol, a mineral oil, petrolatum, a vegetable oil, PPG-15 stearyl ether, PEG-4 dilaurate, lecithin, lanolin, lanolin alcohol, polyoxyl 75 lanolin, cholesterol, cetyl esters wax, cetostearyl alcohol, glyceryl monostearate, triglycerides of capric and caprylic acids, dimethicone, and cyclomethicone. 
(i) grupe koja se sastoji od diizopropil adipata, izopropil miristata, izopropil palmitata, cetearil oktonoata, izopropil izostearata, miristil laktata, oktildodekanola, oleilnog alkohola, mineralnog ulja, amorfnog parafina, biljnog ulja, PPG-15 steril etera, PEG-4 dilaurata, lecitina, lanolina, lanolin alkohola, polioksil 75 lanolina, kolesterola, voska cetil estera, cetostearil alkohola, gliceril monostearata, triglicerida kaprične i kaprilne kiseline, dimetikona 1 ciklometikona; ili (1) diizopropil adipata i oleilnog alkohola;
A benzazepine compound represented by general formula (1) wherein R1 is a group of (1-5): 
je skupina od (1-1): skupina -CO-(CH>),-COR* gdje n je cijeli broj od 1 do 4,
apparatus for transmitting and receiving a signal and method of transmitting and receiving a signal 
UREĐAJI ZA PRIJENOS I PRIMANJE SIGNALA I POSTUPAK ZA PRIJENOS I PRIMANJE SIGNALA
processing the microorganism and/or the micro-organism-rich suspension of step c; 
obrade mikroorganizama i/ili suspenzije bogate mikroorganizmima iz koraka c:
The pharmaceutical composition according to claim 2 or 3 further comprising a lubricating agent. 
Farmaceutska smjesa prema zahtjevu 2 ili 3 koja daje sadrži sredstvo za podmazivanje (lubrikant).
The method of claim 1, wherein the HPV is selected from an HPV group of HPVs consisting of HPV 6, HPV 11, HPV 30, HPV 42, HPV 43, HPV 44, HPV 45, HPV 51, HPV 52 and HPV 54. 
Ingenol 3-angelat ili njegova sol za uporabu prema zahtjevu 3, naznačen time da je virus izabran iz HPV 1, 2, 3, Ingenol 3-angelat ili njegova sol za uporabu prema zahtjevu 3, naznačen time da je virus izabran iz HPV 6, 11, 30, 42, 43, 44, 45, 51, 52 and 54.
The recombinant RSV antigen of any one of paragraphs 1-18, wherein the RSV antigen comprises at least one substitution or addition of a hydrophilic amino acid in a hydrophobic domain of the F protein extracellular domain. 
(li) deleciju jedne ili više aminokiselina u domeni pep27; i (ili) najmanje jednu supstituciju ili adiciju hidrofilne aminokiseline u hidrofobnoj domeni izvanstanične domene F proteina.
It may also be produced in eukaryotic expression systems, such as yeast, insect, or mammalian cells. 
Može biti proizveden i u eukariotskom ekspresijskom sustavu poput stanica kvasca, kukaca ili sisavaca.
The method of claim 1, further comprising administering a second therapy. The method of claim 18, wherein the second therapy comprises administering an agent selected from the group consisting of a) an antagonist of integrin a5B1, b) a cytotoxic/antiproliferative agent, c) an inhibitor of epidermal-derived, fibroblast-derived, or platelet-derived growth factor, d) an inhibitor of VEGF, e) an inhibitor of Flk-1/KDR, Flt-1, Tck/Tie-2, or Tic-1, and f) an inhibitor of phosphoinositide 3-kinase, and a mixture thereof. 
Farmaceutski preparat, koji sadrži spoj prema bilo kojem od prethodnih patentnih zahtjeva ili njegovu farmaceutski prihvatljivu sol ili solvat, i farmaceutski prihvatljiv nosač ili ekscipijens, naznačen time, da farmaceutski preparat opcijski dalje sadrži aktivni sastojak odabran iz skupine koja se sastoji od a) antagonista integrina o5B1, b) citotoksičnog / antiproliferativnog agensa, c) inhibitora faktora rasta izvedenog iz epiderma, izvedenog iz fibroblasta, ili izvedenog iz trombocita, d) inhibitora VEGE, e) inhibitora FIk-1/KDR, FIt-1, Tck/Tie-2 ili Tic-1,1 1) inhibitora fosfoinozitid 3-kinaze i njihove mješavine.
The shell 14 is formed from paperboard and has an internal coating 42 of a thermo-sealable plastic material. 
Ljuska 14 je načinjena od kartona koji ima unutarnju oblogu 42 od plastičnog materijala koji se lijepi kada je vruć.
ADM antibody or an adrenomedullin antibody fragment according to any of embodiments 1 to 9, wherein said antibody or fragment is a human monoclonal antibody or fragment that binds to ADM or an antibody fragment thereof wherein the heavy chain comprises at least one of the sequences: SEQ ID NO: 1 GYTFSRYW 
Anti-Adrenomedulin antitijelo ili fragment anti-ADM antitijela koji se veže na adrenomedulin za uporabu u terapiji akutne bolesti ili akutnog stanja pacijenta prema bilo kojem od zahtjeva 1 do 10, pri čemu spomenuto antitijelo ili fragment je humano monoklonsko antitijelo ili fragment koji se veže na ADM pri čemu teški lanac sadrži sekvence
Liquid pharmaceutical composition 
TEKUĆI FARMACEUTSKI SASTAV
at least one emulsifier is PEG-40 stearate, polysorbate 80 or a mixture thereof, at least one foam stabilizer is methylcellulose, xanthan gum or a mixture thereof, at least one moisturizer is dimethyl isosorbide, propylene glycol or a mixture thereof together with a propellant for the treatment of human skin especially for the treatment of rosacea, acne, atopic dermatitis, contact dermatitis, perioral dermatitis, psoriasis or neurodermitis. 
d) mješavinu PEG-40 stearata i polisorbata 80 kao emulgator, 6) mješavinu metilceluloze i ksantan gume kao stabilizator pjene, f$) mješavinu dimetil izosorbida i propilen glikola kao ovlaživača, do pH 4.5 sa natrijevog hidroksida kao neutralizatora, do 100 pročišćenu vodu kao eksternu faze, 15 i pogonskog sredstva kao pomoćnog sredstva za pjenjenje, naznačena time da je za proizvodnju lijeka pakiranog u spremnik s ispusnim ventilom za liječenje rosacea ili akni.
A method for treating cancer, the method comprising administering to a subject in need thereof an effective amount of a compound represented by the following structural formula: 
; ili njegova farmaceutski prihvatljiva sol. Spoj sukladno zahtjevu 1, naznačen time, da je spoj predstavljen slijedećom strukturnom formulom:
In certain such embodiments of the invention, the compositions can be effectively contained in a package comprising a high density polyethylene (HDPE) container produced using a blow-fill-seal manufacturing technique with a volume capacity of about 1 mL. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 11, naznačen time što je navedeni spremnik za jednu jediničnu dozu oblikovani, napunjeni, pa zapečaćeni spremnik s polietilenom visoke gustoće volumnog kapaciteta od 1,0 ml.
The compound of Claim 9 wherein the condition treated is Type 2 diabetes, Type 1 diabetes, impaired glucose tolerance, hyperglycemia, metabolic syndrome (syndrome X and/or insulin resistance syndrome), glucosuria, metabolic acidosis, arthritis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, short stature due to growth hormone deficiency, infertility due to polycystic ovary syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome; short bowel syndrome; and the prevention of disease progression in Type 2 diabetes. 
Spoj u skladu s patentnim zahtjevom 3 ili upotreba u skladu s patentnim zahtjevom 4, gdje stanje je dijabetes tipa 2, dijabetes tipa 1, smanjena tolerancija glukoze, hiperglikemija, metabolički sindrom (sindrom X i/ili sindrom otpornosti na inzulin), glukozurija, metabolička acidoza, artritis, katarakta, dijabetička neuropatija, dijabetička nefropatija, dijabetička retinopatija, dijabetička kardiomiopatija, pretilost, stanja čpgoršana pretilošću, hipertenzija, hiperlipidemija, ateroskleroza, osteoporoza, osteopenija, fragilnost, gubitak koštane mase, lomovi kostiju, akutni koronarni sindrom, nizak rast zbog nedostatka hormona rasta, neplodnost zbog sindroma policističnih jajnika, anksioznost, depresija, nesanica, kronična zamorenost, epilepsija, poremećaji hranjenja, kronična bol, ovisnost o alkoholu, bolesti povezane s pokretljivošću crijeva, ulceracije, sindrom iritabilnih crijeva, sindrom crijevne upale; te sprječavanje napredovanja bolesti kod dijabetesa tipa 2.
The composition resulting from carrying out the synthetic method comprising: combining a composition comprising an aprotic solvent and a hydroxy-terminated, water-soluble polymer having the following structure: 
(b) sjedinjavanje kompozicije, koja sadrži aprotonsko otapalo i vodotopljivi polimer sa hidroksi grupom na kraju lanca, koji ima slijedeću strukturu:
As the current treatment of asthma and COPD is not satisfactory improved, the problem underlying the present invention was to provide effective and more convenient therapeutic interventions. 
Usprkos tome, sadašnje liječenje astme i KOPB još nije zadovoljavajuće poboljšano i temeljni problem ovog izuma je bio, da dade prikladnije i učinkovitije terapeutske intervencije.
Data acquisition is initiated with a 15 by 15 image format, auto interval, 60 images and a 20sec time delay with a medium resolution. 
Dobivanje podataka je započeto sa 15 na 15 formatu slike, auto intervalu, 60 slika i 20 sekundi vremenskog pomaka uz srednju rezoluciju.
A conjugate molecule comprising one or more compound(s) according to claim 1 or 2 covalently linked to a cell binding agent through the linking group -COOH or of a linker of the compound(s). 
Molekulski konjugat, naznačen time što uključuje jedan ili more spojeva u skladu s patentnim zahtjevom 1 ili 2, kovalentno vezanih na sredstvo za vezanje stanica preko vezne skupine -COOH ili [image] spojnice jednog ili više spojeva.
The antibody of claim 1 or 2 wherein the antibody is an antibody fragment selected from the group consisting of Fab, Fab', F(ab')2, a single-chain antibody (scFv), a dimerized V region (Diabody), and a disulfide-stabilized V region (dsFv). 
Protutijelo u skladu s patentnim zahtjevom 1 ili 2, naznačeno time što je protutijelo fragment protutijela, kojeg se bira iz skupine koju čine Fab, Fab', F(ab'),, jednolančano protutijelo (scFv), dimerizirano V područje (dijatijelo), te disulfidno stabilizirano V područje (dsFv).
at least one float pane with a tin bath side, 
Barem jednog float stakla (1.1) s pokositrenom stranom (II),
The nonwoven fabric according to claim 1, wherein each bonded portion comprises portions of the fibers that are thermally fused together. 
Netkani materijal prema zahtjevu 1, naznačen time da svaki spojeni dio sadrži dijelove vlakana koji su termički spojeni zajedno.
etching at least one pore in the parylene coating on the surface of the head portion of the body, wherein the at least one pore extends from an outer surface of the parylene coating to the surface of the head portion of the body. 
(c) jetkanju najmanje jedna pora u parilenskoj oblozi na površinu glave tijela, gdje se najmanje jedna pora pruža od vanjske površine parilenske obloge do površine glave tijela.